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Abstract
Background: Flow cytometry has been widely used for the diagnosis of various hematopoietic diseases. Although
there have been advances in the number of biomarkers that can be analyzed simultaneously and technologies
that enable fast performance, the diagnostic data are still interpreted by a manual gating strategy. The process is
labor-intensive, time-consuming, and subject to human error.
Results: We used 80 sets of flow cytometry data from 44 healthy donors, 21 patients with chronic lymphocytic
leukemia (CLL), and 15 patients with follicular lymphoma (FL). Approximately 15% of data from each group were
used to build the profiles. Our approach was able to successfully identify 36/37 healthy donor cases, 18/18 CLL
cases, and 12/13 FL cases.
Conclusions: This proof-of-concept study demonstrated that an automated diagnosis of CLL and FL can be
obtained by examining the cell capture rates of a test case using the computational method based on the multiprofile detection algorithm. The testing phase of our system is efficient and can facilitate diagnosis of Blymphocyte neoplasms.

Background
Flow cytometry (FC) involves conjugating fluorochromes
to antibodies, allowing them to bind different cell biomarkers, and passing the stained cells through the path
of a laser where the fluorochromes are excited and fluorescence emission is measured. Forward and side scatter
of cells give information about the size and complexity
of the cells. FC is a valuable tool in the diagnosis of
lymphocytic neoplasms. Most of the current software
supplied by the cytometer manufacturer provides a
2-parameter visual representation of the multi-dimensional data. Pathologists must manually select the areas
that include the cells of interest and view these cells
using two other attributes, a process known as gating.
These areas of interest are not fixed due to instrument,
operator, and sample differences. The pathologists use
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1
Department of Computer Science, University of Houston, Houston, Texas,
USA
Full list of author information is available at the end of the article

the clustering of the cells, the distribution and cell size of
a cluster, and the relative location of the clusters to make
the selection. The process is tedious, time-consuming,
and subject to bias. Thus, there is an urgent need to
develop a fast and unbiased diagnostic approach [1].
Our ultimate goal is to establish an automated process
for clustering cells of interest to replace manual gating
[2,3]. Cell populations can be identified in an automated
fashion (automated gating) by employing clustering
algorithms. The most challenging aspect of the automated process is finding the best clustering algorithm
for high-dimensional data sets [4-7]. Many existing
dimension-reduction approaches may cause useful information to be lost [8-13]. There have been several
attempts to use machine learning technique to automate
the gating process [14-20]. The most commonly used
approach is the k-mean algorithm [21], which assigns a
cell to its nearest cluster. There are several versions of
k-mean algorithms such as fuzzy k-mean, K-medoid,
Gath Geva, and the Gustafson Kessel algorithm [22].

© 2013 Shih et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
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Other common approaches are hierarchical clustering
[23-26] and density-based clustering [27].
Recently, model-based clustering has been gaining
popularity [28-31], including use of the expectationmaximization (EM) algorithm [32]. However, most
approaches only focus on the first stage of FC data analysis that identifies cell populations, some approaches are
only semi-automatic [33], and some only target certain
types of lymphocytic neoplasms [34,35]. This paper proposes a novel 3-dimensional (3-D) 5-parameter model
that detects multiple types of B-lymphocyte neoplasms.
In this proof-of-concept study, we will apply this
methodology to differentiate between selected subtypes
of B-lymphocyte neoplasms and identify biomarkers that
contribute to the classification of certain subtypes, such
as chronic lymphocytic leukemia (CLL) and follicular
lymphoma (FL). Our goal is to develop software solutions to allow pathologists to quickly interpret the FC
data without bias.

Methods
A multi-profile approach for lymphoma detection

The multi-profile lymphoma detection described in this
article can detect whether the FC data of an individual
matches the profile of a particular type of lymphoma or
that of a healthy donor. The objectives of the computational detection system were: (1) minimum human
intervention in the detection process, (2) ability to
detect various types of B-lymphocyte neoplasms, (3) efficient computation complexity, and (4) reasonable detection rate with a low false-negative rate.
Our system is a multi-anomaly detection system in
which a healthy subject’s profile and several anomaly
profiles are used to determine the closest match. We
will first describe a single profile detection system. The
system must be trained with known data to gain knowledge about a healthy donor and a patient with a particular type of lymphoma. To achieve the goal of diagnosis,
the system has to learn the profile of healthy donors
through a training phase and match the profile to the
test subject through a fitting (testing) phase. The profile
building and fitting will be discussed later. The overall
strategy of the testing is summarized in Figure 1. The
FC data is categorized into three groups: normal donor,
patients with CLL, and patients with FL. A “profile
building algorithm” is used to capture the attributes of
one individual group, and the profile is a collection of
ellipsoids defined on the cytometry map of selected
attributes. These ellipsoids are the area of the map
where the cells concentrate. One can imagine the profile
as a multi-dimensional ellipsoid which filters out some
of the fringe outlier cells. A “fitting algorithm” is used
to compare a test subject with the profile. Certain features of the profile and the test data have to be
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extracted for comparison. We needed a metric to measure the fitness of the profile and the test case, defined
as the cell capture rate (CCR). This is the ratio of the
number of cells captured inside the ellipsoid(s) to that
of cells within the test clusters. How the CCR was calculated will be explained in a subsequent section. The
CCR estimates how good a test subject matches the profile of healthy donors. Ideally, in a single-profile system,
most of the test cells should fall within the ellipsoids
defined in the normal profile, thus we can use the CCR
to determine if the test case matches the normal profile.
In a multi-profile detection system, a test subject then
has a vector that includes three CCRs, one each for the
normal, CLL, and FL profiles. We will use the vector to
diagnose the outcome of the test subject.
A 3-D 5-parameter flow cytometry data model

Our system focused on characterizing B lymphocyte
neoplasms to develop a model-based clustering
approach to identify normal or abnormal B cell populations that share similar biological functions. There were
two steps in the pre-processing: (1) removal of the
doublets (Figure 2) and (2) selecting the lymphocytes
(Figure 3). The algorithm for removing the doublets is
relatively simple and can be found in [36]. Our system
was designed to learn from the user’s knowledge and to
select and classify these cells automatically. There were
five Cluster of Differentiation (CD) biomarkers that
were used for data modelling: CD5 (labelled with
PerCP), CD10 (APC), CD19 (APC-Cy7), kappa light
chain (PE), and lambda light chain (FITC). In addition,
CD45-AmCyan was used for lymphocyte gating. Normal
B lymphocytes are positive for CD19, but not express
(negative for) CD5 and CD10, and composed of nearly
even populations of cells expressing kappa or lambda
light chains. In CLL, the lymphoma cells are positive for
CD19 and CD5, but negative for CD10. In contrast, FL
cells are positive for CD19 and CD10, but negative for
CD5. Importantly, cells of CLL and FL exhibit kappa or
lambda light chain restriction (a feature of malignancy).
The five lymphocytic biomarkers were combined into a
3-D image as shown in Figure 4. The x-axis represents
kappa light chain and lambda light chain. The y-axis
represents CD19, a pan-B cell marker. The z-axis is
used for CD5 and CD10 expression. Since a B lymphocyte is either kappa light chain or lambda light chain
positive, we subtracted the value of kappa by lambda to
eliminate the background signal; likewise, the value of
CD5 minus CD10 is presented in the z-axis. We use the
notation of “Lambda+” and “Kappa+” to indicate the difference in expression between the two CD biomarkers.
A cell with a Lambda+ value in Figure 4 means the cell
is expressing Lambda, and lacking Kappa expression.
“CD5+” and “CD10+” are used in the figure in a similar
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Figure 1 Overview of the methodology. Different FC data sets are used to build the profiles. Test cases are fitted to the three profiles and the
fitting algorithm produces three CCRs. According to the three CCRs, the system gives the diagnosis.

Figure 2 Removing doublets by forward scatter high (FSC-H) and forward scatter area (FSC-A). (a) Before removing doublets and (b) after.
The doublets were most likely generated by mechanical error and/or sampling issues.
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Figure 3 Gating lymphocytes. (a) Lymphocytes are gated (circled) by CD45 and SSC-A plots. (b) Selected lymphocytes from (a).

fashion. For y-axis, only one biomarker is used, and the
cell expressed with CD19 is noted as “CD19+”. By analyzing the digital FC data in this novel 3-D 5-parameter
model, lymphoma cells can be easily distinguished from
the normal cell population and further classified into

three sub-types: (a) B cell lymphoma with immunophenotyping prolife CD5+, no CD10-expression, light chain
restriction (expressing kappa or lambda alone): this profile could be seen in CLL, small lymphocytic lymphoma
(SLL), mantle cell lymphoma (MCL), and CD5+ diffuse
large B cell lymphoma (DLBCL), (b) B-cell lymphoma
with immunophenoting prolife CD10+, no CD5-expression,
light chain restriction: this profile is specific for FL, Burkitt
lymphoma, and CD10+ DLBCL, and (c) B-cell lymphoma
with immunophenotyping prolife no CD5- or CD10expression, light chain restriction: including MCL, DLBCL,
and other non-classified B cell lymphomas. Notably, this
model is expandable and can be used to analyze any type of
B lymphocyte neoplasm. For proof-of-concept demonstration, the two most common B cell lymphomas, CLL and
FL, were studied. We will include additional neoplasms as
the data becomes available.
Profile building

Figure 4 A novel 3-D 5-parameter model. The 3-D data view with
5-parameters of CD5, CD10, CD19, Kappa, and Lambda light chains.
CD biomarker expression with “+” indicates the difference in
expression between two CD biomarkers, e.g., a cell with a CD5+
value means the cell is expressing CD5, and lacking CD10 expression.

After removing the doublets and selecting the lymphocytes by gating on CD45 and side scatter, the healthy
donors’ FC data was plotted using the 3-D 5-parameter
model defined above (see Figure 5). Our objective was
to identify all clusters so that the lymphocytes can be
characterized by the clusters in the 3-D 5-parameter
model. In Figure 5, a healthy donor’s cells form three
clusters: (1) pink cells: B lymphocytes expressing kappa
light chain, (2) blue cells: B lymphocytes expressing
lambda light chain, and (3) green cells: T lymphocytes.
The EM algorithm was used to cluster the cells because
it gave better results in most of our cases. We used the
EM algorithm to produce the final clustering result with
means and covariances, and an ellipsoid was constructed
with the means and covariances of clusters. The means
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Figure 5 Lymphocytes in the 3-D 5-parameter data view model. Lymphocytes from a representative healthy donor. (1) pink cells: B
lymphocytes expressing kappa light chain, (2) blue cells: B lymphocytes expressing lambda light chain, and (3) green cells: T lymphocytes
lacking CD19 expression.

gave us the center of the ellipsoid and the covariances
gave us the orientation and the shape of the ellipsoid.
The standard deviation dictated the size of the ellipsoid.
Once the means, covariances, and standard deviation
were determined, the three ellipsoids for healthy donors
were constructed (Figure 6). In other words, the orientation, size, and location of the ellipsoid were considered as
the profile of this cluster of healthy donors.
The details of the algorithm are listed below.
Input:
n: number of observations
d: number of attributes in the observation (3 in the
3-D 5-P model)
k: number of clusters (k = 3 for normal profile and
k = 2 for patient profile)
X[i, j]: observation data of size n × d, i = 1, ..., n and
j = 1, ..., 3.
m: multiplier for the standard deviation used to determine the size of the ellipsoids (m = 2 in our analysis)
Output: k ellipsoids containing data points within
m × std of the centers of the clusters represented by:
W[c]: percentage of the data points in cluster c,
c = 1, ..., k.

M[c, i]: the i-th attribute of the of the c-th mean of
the cluster (k × d)
V[c, i, j]: the co-variance matrix of the c-th cluster
(k × d × d)
Step 1: [Initialization] Given X, use the K-mean algorithm to find k clusters of X. The output of K-mean are:
M (i) , V (i) and W (i) , the means, co-variance, and the
weight of the k clusters.
Step 2: [Clustering] Use the EM (expectation maximization) algorithm to compute a better clustering of ×
with initial values M = M(i), V = V(i), and W = W(i).
Step 3: [Ellipsoid Construction] Construct k ellipsoids
with Means M and Co-variance V and weight W. The
ellipsoid should include all data points within m × std
of the center of its cluster.
The process of building a cancer patient’s profile
(ellipsoids) was the same as that for the healthy donors
except the training data were selected from patient
cases. However, the modelling of the patient’s profile
was more complicated. Although most healthy donors
show very similar representation in the 3-D 5-parameter
model, CLL data are more diverse, most likely due to
different stages and severity of disease. While healthy
donors have two cell clusters for kappa and lambda
light chains, CLL patients show only one cluster because

Shih et al. BMC Genomics 2013, 14(Suppl 7):S1
http://www.biomedcentral.com/1471-2164/14/S7/S1

Page 6 of 16

Figure 6 Lymphocytes in 3-D 5-parameter data view model. This is an example of using the normal profile to test a healthy donor. The
normal profile is represented as three clusters. The corresponding 2-D projections are also provided for review.

lymphoma cells are restricted to either kappa or lambda
light chains. Thus, in the profile-building algorithm,
there are only 2 clusters (k = 2) instead of 3 clusters.
For example, in Figure 7a, CLL patient 453 only showed
one cluster of cells expressing kappa light chain, which
is defined as kappa dominant; in Figure 7b, CLL patient
338 showed B cells that were lambda light chain dominant. It is very important to have a good CLL profile to
test the subjects, and this can be cross validated by subsequent experiments.
The FL profile was built by a similar approach, but
both clusters 1 and 2 cells are present in only the CD10
+ side of the z-axis (CD5-CD10) since FL cells express
only CD10 and lack CD5 expression. For example, in
Figure 8a, FL patient 1444 only showed one cluster in
the kappa light chain and is defined as kappa dominant.
In Figure 8b, FL patient 1284 showed B lymphocytes
that were lambda light chain dominant.

Profile-fitting algorithm

Once we had constructed the normal profile, a test case
(Figure 9b) was “fitted” to the profile (Figure 9a). Our
goal was to use these ellipsoids to capture cells of a test
case, and count the numbers of captured cells inside an
ellipsoid. After the means and co-variances were computed by the normal profile building algorithm, the
three profiles were represented as ellipsoids (Figure 9a).
However, due to manual handling of the samples, environmental conditions, and the calibration of the instrument, the cell clusters and the ellipsoids may not align
very well. An example of cells of a normal test case
overlaid with the three-ellipsoid profile is shown in
Figure 9c. Thus, a fitting algorithm was required to realign the cell clusters to match with the ellipsoids.
The ratio of the number of cells captured inside the
ellipsoid(s) and that of cells of the test clusters is
defined as the CCR of the profile on the test case. In
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Figure 7 CLL profile. The CLL profile is represented as two clusters: kappa chain-restricted (a) and lambda chain-restricted (b).

other words, the ratio calculation requires two numbers:
the number of B cells and the number of overall cells.
The number of cells captured by a profile ellipsoid can
be used as the numerator of CCR. For the denominator,
there are three possibilities: all blood cells, all lymphocytes,

or B cells. In the next two paragraphs, we shall describe
how the CCR is computed.
To find out the B cells captured by an ellipsoid in the
profile, it was necessary to partition the cells into clusters. However, most clustering algorithms are ineffective
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Figure 8 FL profile. The FL profile is represented as two clusters: kappa chain-restricted (a) and lambda chain-restricted (b).

in dealing with clusters that are very close or intersecting each other. Thus, our first step was to use a hierarchical divisive clustering ("top-down”) approach by
separating the T cells from the rest of the test cells by
using the value of CD19. The parameter k is defined as

the number of clusters (k = 3 for normal profile and
k = 2 for patient profile) and X[c,j] represents the observation data of c-th cell. In the first step, T cells were
identified and assigned with a label k. The next step was
to find the center of the T cells. This can be easily
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Figure 9 Testing process. The process of using the healthy profile to test a normal subject with shifting cells. (a) A normal profile with 3
ellipsoids (b) A normal test case before alignment with the normal profile (c), and after alignment with the normal profile (d).

achieved by calculating the mean of cells with label k.
Technical variation, such as different operators,
machines, etc., may cause the data to shift. Thus, the
third step of alignment is to fix the variation by moving
the profile to “fit” the test data. We have tried several
methods for alignment. In one approach for fitting the
normal profile, we divided B cells into two clusters
representing lambda light chain dominant and kappa
light chain dominant and obtained the centers of the
two clusters. Then we aligned the ellipsoids individually
to the corresponding center. This approach fails to
detect changes in the distance between clusters. In addition, the clustering algorithm used to separate two clusters that are very closely aligned was not very effective
and this may result in misclassifications. In our current
work, we adopted a hierarchical approach: we first
found the center of the T cells in the test case, and then
calculated the difference between center of T cells in
the profile and test case. Finally, we aligned all ellipsoids
by the difference. In our system, we used only the one
or two ellipsoids that represent B cells and left out the
ellipsoid that represents T cells since we are detecting B
lymphocyte neoplasms. After aligning the ellipsoids to
the center of the corresponding clusters, we obtained
the numbers of the captured B cells, which is the
numerator of the CCR.
For the denominator of the CCR, we tried out all the
three possibilities mentioned above. If we use the total
number of the blood cells as the denominator, the CCR
is compressed to a small range thus it is difficult to distinguish healthy donors and patients. In a preliminary
paper we reported [37], the B cell CCR is calculated by
the number of B cells inside the ellipsoid divided by the
total number of lymphocytes.
That approach gave us a higher CCR to compare since
the denominator is smaller. Even though the CCR in
[37] was able to distinguish the patients from healthy
donors, the CCR for healthy donor using the normal
profile is somewhat small (about 13% on average). In
this paper, we decide to use a third approach by using

the total number of B cells as the denominator. This
approach gives us a much higher CCR for healthy donor
compared with the normal profile (over 80% on
average).
The detail of the fitting process is given below, and
the final B cell CCR is defined as the ratio of the number of B cells inside the ellipsoid over the total number
of B cells. Input:
n: total number of observations
k: number of clusters (k = 3 for normal profile and
k = 2 for patient profile)
d: number of attributes in the observation (d = 3)
X[c, j]: observation data of the c-th cell, c = 1, .., n,
and j = 1, ..., d.
P: a Profile (Normal, CLL, or FL) including M[c,j]
and V[c,i,j], c = 1, ..., k.
Output: Cell capture rate of × against the profile P.
Algorithm:
Step 1: [Clustering of cells] This is achieved by a hierarchical divisive clustering approach to identify the Tcells with the CD19 first. Let cluster[c] be the cluster of
cell c, thus cluster[c]=k for all cell c in the T-cell cluster.
For the rest of the cells, use the K-mean algorithm on
X[c,j] to find the remaining k-1 cluster(s). The B-cell
clusters are numbered as cluster 1, .. , k-1.
Step 2: [Finding the centers] For each cluster, find the
center MC[c, i] (c = 1, ..., k, i = 1, ..., d) of the cluster by
computing the mean of the cells in that cluster i.
Step 3: [Alignment] Find the difference δ[k,i] of T[k,i],
the centers of the T-cell clusters and M[k,i] the centers
of the T-cells of the profile P. Modify the means so that
the T-cell cluster aligns with the T-cell ellipsoid, i. e.,
M[c,i] = M[c,i]+ δ[k,i].
Step 4: [Calculating CCR] Computing the cell capture
rate (CCR) of B-cell as:
k−1
th
= 1 (number of cells in the c ellipsoid)
CCR = c k−1
th
c = 1 (number of cells in the c cluster)
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Diagnosis

More formally, we defined the diagnosis decision process by finding the distance of the CCR vector to the
axes. The algorithm is described in the equations below.
Let D = {Normal, CLL, FL} be the set of all diagnoses,
and CCRj be the CCR for each j in D. Compute the distance from the CCR vector of a test case to the corresponding axis as

di =
CCR2j ,
j = i

and
Diagnosis = arg min di .
i∈D

The algorithm calculates and selects the axis with the
smallest distance to the CCR of the test case.

Results
Single-profile testing

Single-profile testing means testing against only the normal healthy profile. We used 72 data sets from 36
healthy donors, 21 CLL patients, and 15 FL patients in
our experiment. We constructed the normal profile with
12 randomly selected healthy donors and tested it with
the remaining 60 cases. Our hypothesis was that the
CCR computed in the fitting algorithm of the healthy
cases would fit the normal model better than the patient
cases. The result is shown in Figure 10. By comparing
the CCRs, the CLL cases were distinguishable from the
healthy subjects, but there was overlap between the
healthy donors and FL patients. Thus, we were not able
to identify all patient samples using only the normal
profile. To improve these results, we used multi-profile
testing, which combines the results of testing against all
three profiles (normal, CLL, and FL).
Multi-profile testing with cross validation

The hypothesis to be tested was that the healthy donors’
cases would capture more cells using the healthy subject
model, and patients’ cases would capture more cells
using the patient model. In Figure 11 we show a test
case (healthy subject) against all three profiles, and as it
is a healthy subject, the normal profile fits better.
The unresolved issue is how to select a suitable profile
to best represent the healthy donors, and CLL and FL
patients. Building normal profiles is easier since samples
from healthy donors are generally consistent and less
variable; building patient profiles is more difficult since
patient samples can vary dramatically. As a first step we
used cross validation to test our approach. Because of
the differences noted previously, we used a 3-fold cross
validation for building and fitting the normal profile,
and leave-one-out cross validation for building and

Figure 10 Single profile testing. The box plot of 60 cases (24
healthy donors, 21 CLL patient cases, and 15 FL patient cases) fitted
against the normal profile is shown. The central mark is the median,
the edges of the box are 25th and 75th percentiles, and the
whiskers extend to the most extreme data points. The outlier
subjects are marked as red “+”. The default maximum whisker
length is 1.5. Points are drawn as outliers if they are larger than q3
+ 1.5 × (q3 - q1) or smaller than q1 - 1.5 × (q3 - q1), where q1 and
q3 are the 25th and 75th percentiles, respectively. In this figure, CLL
and FL data give lower CCR rates since they do not fit the normal
profile well.
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Figure 11 A test case (healthy) fitted by three profiles. Figure (a) is a healthy test case. Three profiles, normal, CLL, and FL were fit to the
healthy test case. The healthy sample (b) shows alignment, while the CLL and FL profiles do not align (c and d, respectively).

fitting the disease profile. We did not use the leave-oneout method for healthy profile testing for two reasons:
(1) leave-one-out will create a lot more cases, and (2)
healthy donor samples are more homogenous than CLL
and FL cases. Thus we use a 3-fold validation technique
for the testing against the normal profile. In this experiment, we used the same 72 data sets from 36 healthy
donors, 21 CLL patients, and 15 FL patients (summarized in Table 1). The normal profile is built by merging
12 healthy donors (3-fold) and processed by our profilebuilding algorithm. Then 60 CCRnormal (from testing the
24 remaining healthy donors, 21 CLL patients, and 15
FL patients) are obtained by processing our profile-fitting algorithm. Since it is 3-fold cross validation, we
then have 180 CCRnormal (72 normal, 63 CLL, and 45
FL). The CLL profile is built by every CLL subject

(leave-one-out) and processed by our profile-building
algorithm. Then 72 CCR CLL (from testing 36 healthy
donors, 20 remaining CLL patients, and 15 FL patients)
obtained by processing our profile-fitting algorithm.
Since it is leave-one-out cross validation, we then have
1491 CCR CLL (756 normal, 420 CLL, and 315 FL).
Doing similar processes for FL patients, we then have
1065 CCRFL (540 normal, 315 CLL, and 210 FL). Averaging the CCR produces the results shown in Table 2.
The average of the 108 CCR normal is 69.9%, which
means 69.9% of B cells are inside the normal ellipsoid/
profile for healthy donors. In other words, 69.9% of the
B cells can be captured by our normal profile. The CLL
profile has a 39.5% capture rate for CLL cases, and the
FL profile has a 65.7% capture for FL cases. For each
test case, we obtained three cell capture rates
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Table 1 Cross validation.

Table 3 Accuracy.
Profile

Normal
3-fold
Total
Cases
Training
Testing

Profile

CLL
Leave-one-out
36

21

15

12
(24+21+15)x3 =
180

1
(36+20+15)x21 =
1491

1
(36+21+14)x15 =
1065

The table shows case information. By using cross validation, there are 12
cases (3-fold) trained to build the normal profile, and 1 case (leave-one-out)
trained to build the patient profile.

(CCRNormal, CCRCLL, and CCRFL). By applying the diagnosis decision formula, our system decides which profiles fit better. Based on the cross validation, there are
54,810 test cases and the result is shown in Table 3.
Our system can identify 80.7% of healthy donors from
all the healthy donors, 61.1% of CLL patients among all
the CLL patients, and 64.5% of FL patients among all
the FL patients.
Since we adopted the leave-one-out approach for
building for the CLL and FL profiles, some of the cancer
patients fit the profile better than others. A more carefully selected profile is needed to improve the accuracy
of the diagnosis, which is discussed in the next section.
Multi-profile testing with a data selection strategy for
profile building

As mentioned previously, there is no need to pre-select
healthy donors to build the normal profile since healthy
donors’ samples are fairly consistent in composition. To
choose a better ellipsoid to represent the CLL, we used
the distance between the center of cluster 3 to 1 (or 2)
as our selecting criteria in Figure 7a and 7b. We selected
approximately 15% of the CLL cases that have a closer
value to the mean of the distance. For FL (Figure 8), we
will perform the same process to pre-select 15% of FL
data for our training cases. The CLL and FL profiles are
built by merging the training cases.
Table 2 Average CCR.
Profile
Average CCR

Test

Accuracy

FL
Leave-one-out

Normal
12 Cases

CLL
1 Case

FL
1 Case

Normal
1368 events

69.9%

9.9%

27.6%

CLL
798 events

22.5%

39.5%

14.2%

FL
570 events

48.5%

Test

Normal

CLL

FL

Normal
22,680 events

80.7%

2.2%

16.6%

CLL
18,900 events

23.3%

61.1%

15.6%

FL
13,230 events

32.2%

0.6%

64.5%

By applying the diagnosis decision formula, the system decides that each
event belongs to one decision (normal, CLL, or FL). The table shows the
accuracy. For the FL patients, 8,533 (64.5%) events were diagnosed correctly.

In this experiment, we used 80 data sets from 44
healthy donors, 21 CLL patients, and 15 FL patients (see
Table 4). We used the pre-selected 15% of data to build
the profile, and tested the remaining 68 cases. In Figure
12, the average CCR shows a higher value than the average data listed in Table 2. For each test case, we
obtained three CCRs. We plotted the test cases using
the three CCRs and they clustered in three regions in 3D space (Figure 13). Because the CCR of the matched
profile gave a much higher value than the unmatched
ones, most of the test cases were very close to the axis
representing the corresponding profile. The final result
is shown in Table 5. Our system successfully identified
36 out of 37 normal cases, 18 out of 18 CLL cases, and
12 out of 13 FL cases.

Conclusions
As a proof-of-concept study, we have demonstrated a
multi-profile B lymphocyte neoplasm analysis methodology to automate the detection of certain types of B lymphocyte neoplasms by FC. A profiling method was
described that characterized both the healthy donors
and patients with different types of B-lymphocyte neoplasms. A CCR was defined to measure the fitness of a
test case against the profile. We have demonstrated that
one can obtain an automated diagnosis of CLL and FL
by examining the CCRs of a test case against all three
profiles. Although we only looked at FL and CLL in this
study, this novel 3-D 5-parameter detection system
should be capable of identifying other types of B
Table 4 Multi-profile testing with data selection strategy
for profile building.
Profile

7.9%

65.7%

The 69.9% is obtained by averaging the 72 healthy donors’ CCRnormal; 9.9% is
obtained by averaging the 756 healthy donors’ CCRCLL; 27.6 % is obtained by
averaging the 540 healthy donors’ CCRFL. From this table, healthy donors fit
the normal profile better and test samples fit patient profiles better.

Normal

CLL

FL

Total Cases

44

21

15

Training

7

3

2

Testing

37

18

13

The table shows the number of cases used to build profiles (7 cases for
building normal profile, 3 cases for building CLL profile, and 2 cases for
building FL profile). The remaining cases are used for testing purpose.
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Figure 12 Multi-profile testing. The box plot shown represents 60 cases (24 healthy donors, 21 CLL patient cases, and 15 FL patient cases)
fitted to the normal, CLL, and FL profiles. The box plot shows the normal data fits the normal profile better, the CLL data fits the CLL profile
better, and the FL data fits the FL profile better.

lymphocyte neoplasms. Moreover, since the analysis is
computational, it is possible to track FC data for monitoring disease progression of a lymphoma patient.
Additionally, this 3-D 5-parameter detection system provides a novel way for pathologists to interpret FC data.
Instead of manually gating on numerous 2-parameter
plots, they can analyze 5-parameters in a 3-D image that
can be rotated and viewed from various angles. This
would allow them to see small clusters of cells that may be
obscured in a 2-D image. In this way the 3-D 5-parameter
detection system has the potential to improve a process
that is labor-intensive, time-consuming, and subject to
human error through automation and improved data
interpretation.
This article is an expanded paper previously presented
at the 2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences
(ICCABS) [37]. We expanded the preliminary result
presented at the ICCABS conference and added the

following new components. 1. Detail algorithms of our
method: In the ICCABS paper, we only included the
brief descriptions of building profiles and using the profile to test a new subject. In our current submission, we
have included the detail steps of the Profile Building
Algorithm and Fitting Algorithm. 2. Additional experimental results: After collecting more data from the
Methodist Hospital, we added 7 more FL patient cases
which almost doubled the FL sample size. 3. A comprehensive analysis including cross-validation of the testing:
In the current submission, we added (a) Single-Profile
Testing, (b) Multi-Profile Testing with Cross Validation,
(c) A data selection strategy for profile building which
yields better profiles for CLL and FL. 4: New definition
of the B cell CCR: the B cell CCR is calculated by the
number of B cells inside the ellipsoid divided by the
total number of lymphocytes. 5. Other Improvements:
We presented a new overview of the methodology
which gives a better explanation of the system, and we
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Figure 13 Result using three profiles. All 68 data sets were plotted using the three cell capture rates (CCR Normal, CCRCLL, and CCRFL). The
majority of test cases aligned to only one axis (only two cases are misclassified).

used box plots to compare the cell capture rate of using
various profiles. This gives reader a better understanding
of the distribution of the CCRs.

Table 5 Accuracy.
Profile
Accuracy

Test

Normal
7 Cases

CLL
3 Cases

FL
2 Cases

Count

%

Count

%

Count

%

Normal
37 Cases

36

97.3%

0

0%

1

2.7%

CLL
18 Cases

0

0%

18

100%

0

0%

FL
13 Cases

1

7.7%

0

0%

12

92.3%

Our system successfully identified 36/37 normal cases, 18/18 CLL cases, and
12/13 FL cases.
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